SEC Form 4 · accession 0001209191-16-130093
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lewis Clayton Cantley Jr.
Director
Period of report
Jun 27, 2016
Accepted (ET)
Jun 29, 2016 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Jun 27, 2016 | S | 627 | $40.37 | D | 125,921 | D | |
| Common stockF2,F3 | Jun 27, 2016 | S | 625 | $40.37 | D | 125,943 | I | See footnote |
| Common stockF4 | Jun 28, 2016 | S | 627 | $43.38 | D | 125,294 | D | |
| Common stockF4,F3 | Jun 28, 2016 | S | 625 | $43.38 | D | 125,318 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $40.08 to $40.71. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Shares held by Vicki Lee Sato, who is the reporting person's spouse.
- F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $42.78 to $43.68. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.